daraxonrasib

Phase 3Recruiting

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Pancreatic Cancer

Conditions

Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Resected Pancreatic Adenocarcinoma

Trial Timeline

Dec 15, 2025 → Jul 10, 2030

NCT ID

NCT07252232

About daraxonrasib

daraxonrasib is a phase 3 stage product being developed by REVOLUTION Medicines for Pancreatic Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07252232. Target conditions include Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07252232	Phase 3	Recruiting	Dec 15, 2025	Jul 10, 2030	Pancreatic Cancer

Competing Products

20 competing products in Pancreatic Cancer

See all competitors

Product	Company	Stage	Hype Score
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + Bendamustine	Lonza	Phase 1	30
pemetrexed	Eli Lilly	Phase 2	52
mFOLFIRINOX + Ramucirumab	Eli Lilly	Phase 2	52
[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359	Perspective Therapeutics	Phase 1/2	33
Zentalis + Gemzar	Zentalis Pharmaceuticals	Phase 2	44
enzastaurin + gemcitabine	Eli Lilly	Phase 2	52
Cyclophosphamide + GVAX Pancreas Vaccine (GVAX) + Pembrolizumab + IMC-CS4	Eli Lilly	Phase 1	33
Ramucirumab	Eli Lilly	Phase 1/2	41
GEMZAR + ALIMTA	Eli Lilly	Phase 3	77
CS-1008 (humanized anti-DR5 antibody) + gemcitabine	Daiichi Sankyo	Phase 2	52
exatecan mesylate	Daiichi Sankyo	Phase 2	52
exatecan mesylate + gemcitabine hydrochloride	Daiichi Sankyo	Phase 3	77
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	52
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	52
AGS-1C4D4 + gemcitabine	Astellas Pharma	Phase 2	52
erlotinib + gemcitabine + nab-paclitaxel	Astellas Pharma	Phase 1	33
erlotinib hydrochloride + gemcitabine hydrochloride	Astellas Pharma	Phase 1	33
AGS-1C4D4 + Gemcitabine	Astellas Pharma	Phase 2	52
Tarceva (erlotinib HCl, OSI-774)	Astellas Pharma	Phase 3	77
Enzalutamide + Gemcitabine + Nab-paclitaxel	Astellas Pharma	Phase 1	33

Other Products from REVOLUTION Medicines

daraxonrasib + docetaxelPhase 3

RMC-6236 + Gemcitabine + nab-paclitaxel + Irinotecan + Liposomal irinotecan + 5-fluorouracil + leucovorin + OxaliplatinPhase 3

RMC-6291 + RMC-6236 + Pembrolizumab + Cisplatin + Carboplatin + Pemetrexed + RMC-9805Phase 1/2

Elironrasib + DaraxonrasibPhase 1/2

TNG462 + RMC-9805 + RMC-6236 + mFOLFIRINOX + gemcitabine/nab-paclitaxelPhase 1/2